Hinge Health Inc. (HNGE) Shares Rise 17.2% Following Latest Earnings: Will the Momentum Persist?

Hinge Health Inc. Surges 17.2% Since Last Earnings—What’s Next?

Over the Per the past month, shares of Hinge Health Inc. (HNGE) have climbed approximately 17.2%, outpacing the S&P 500’s performance. This notable rally has investors questioning whether the momentum will persist as the next earnings report approaches, or if a correction is on the textile.

Review of Recent Earnings Results

In the fourth quarter of 2025, Hinge Health delivered earnings per share of $0.49, surpassing the Zacks Consensus Estimate of $0.42 by 16.7%.

For the full year 2025, the company reported a GAAP net loss per share of $7.77, a significant increase from the prior year’s $0.86 loss. This wider loss was largely attributed to expenses related to the IPO and stock-based compensation. However, management expressed confidence in achieving GAAP profitability in 2026, building on the profitable fourth quarter.

Revenue Performance

Fourth-quarter revenue reached $170.7 million, marking a 46% increase year-over-year and exceeding consensus expectations by 8.5%. The robust growth was fueled by improved yields and a larger base of contracted lives.

Annual revenue for 2025 rose 51% to $587.9 million, up from $390.4 million in 2024. Last twelve months (LTM) calculated billings totaled $671 million, reflecting a 44% year-over-year increase.

By the end of 2025, Hinge Health served around 24.6 million contracted lives across more than 2,800 clients, a 24% rise from the previous year. The average number of eligible lives over the LTM was 20.1 million, supporting 783,000 members—a 47% jump from 2024. Client retention remained strong at 97%, with net dollar retention above 110%.

Margins and Profitability

Gross margin improved to 85% in the fourth quarter, up from 82% a year earlier. Operating margin also strengthened, reaching 28% compared to 18% in the prior year. For the full year, operating margin stood at 20%, a significant turnaround from negative 7% in 2024.

Financial Health

Free cash flow for the fourth quarter was $62 million, representing a 36% margin. For the year, free cash flow totaled $180 million, up from $45 million in 2024. The company ended 2025 with $479 million in cash and equivalents.

Guidance for 2026

Looking ahead, Hinge Health anticipates first-quarter 2026 revenue between $171 million and $173 million, with adjusted operating income projected at $30–$32 million. For the full year, revenue is expected to reach $732–$742 million, representing 25% growth at the midpoint, and operating income is forecasted at $151–$156 million.

Analyst Estimate Revisions

Over the past month, analyst estimates for Hinge Health have been revised upward. The consensus estimate has increased by 118.18% during this period, reflecting growing optimism.

VGM Score Overview

Currently, Hinge Health holds a Growth Score of C, but its Momentum Score is lower at D. On the value front, the stock received an F, placing it in the lowest quintile for this investment style. Overall, the aggregate VGM Score is F, which is most relevant for investors not focused on a single strategy.

Future Prospects

With estimates trending higher and the scale of revisions looking favorable, Hinge Health Inc. has earned a Zacks Rank #2 (Buy). The outlook suggests the stock could deliver above-average returns in the coming months.

Spotlight on a Top Semiconductor Pick

There’s a lesser-known company in the semiconductor sector, offering products that industry giants like NVIDIA do not. Positioned to capitalize on the next wave of market expansion, this company is just starting to gain attention—an ideal time for investors.

With robust earnings growth and a rapidly expanding customer base, the company is well placed to meet soaring demand for Artificial Intelligence, Machine Learning, and the Internet of Things. The global semiconductor market is forecasted to grow from $452 billion in 2021 to $971 billion by 2028.